BioNTech Announces Positive Topline Phase II Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma

BioNTech SE announced positive topline data from the ongoing Phase II clinical trial in patients with unresectable stage III or IV melanoma whose disease had progressed following anti-PD-(L)1-containing treatment.